Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2023 17:00 ET | Source: Custom Market Insights

[Latest] Global Antibacterial Drugs Market Size/Share Worth USD 67.9 Billion by 2032 at a 5.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Antibacterial Drugs Market Size, Trends and Insights By Drug Class...
October 30, 2017 08:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States

NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
October 24, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
October 04, 2017 13:13 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek

NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
September 25, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections

NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
September 22, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Participate in Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
September 18, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
June 01, 2017 14:42 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe

New Haven, Conn, June 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five...
March 02, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
February 27, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Provides Baxdela NDA Update

NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...

Next Page keyboard_arrow_right